| Name | Title | Contact Details |
|---|
GlucoTrack, Inc (formerly known as Integrity Applications, Inc.) is focused on the design, development, and commercialization of novel technologies for people with diabetes and prediabetes. The Company`s initial product, GlucoTrack®, is a proprietary non-invasive glucose monitoring device designed to obtain glucose level measurements without the pain, incremental cost, difficulty, or discomfort of conventional invasive finger stick devices.
SpineFrontier Inc. is a growing medical device company that designs, develops and markets implants and instruments that equip surgeons to perform the least invasive spine surgery. SpineFrontier`s innovative and disruptive technologies and techniques apply the Less Exposure Surgery (LES) philosophy to solve clinical problems and make the surgeries safer for the patient and easier for the surgeon. Surgeries can be done in an outpatient center and patients can be discharged same day with rapid recovery, due to less disruption of normal tissues and less time in surgery. We believe LESS is more. LESS time in treatment and recovery is MORE time in action for our patients and surgeons. SpineFrontier is headquartered in Beverly, Massachusetts. It was founded in 2006, and released its first products in 2008. SpineFrontier is a KICventures portfolio company and the exclusive manufacturer of LESS technologies and instruments for surgeon members practicing in the LESS Institute global outpatient network.
Advance Medical Designs Inc is a Marietta, GA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Sonendo, Inc. is a privately held, venture-backed company developing innovative technologies to transform endodontic therapy. Sonendo`s Multisonic Ultracleaning technology addresses the challenges that currently exist in endodontic treatment, offering a solution to the problems that exist within traditional root canal therapy.
The Miromatrix Medical technology has the potential to enable the creation of fully biological replacement organs for the human body. In addition to the Company’s internal efforts focused on the development of its first product – a biological mesh for hernia repair – scientists around the globe are working with the Company’s technology and are taking critical steps toward the creation of human organs including the liver, lung, kidney, pancreas and heart. While our biological mesh development program has been conducted internally, our intent is for current and future products to be developed both at Miromatrix and in partnership with the best among those external groups already working with our technology in order to utilize this pre-existing expertise to develop individual products in the most efficacious, cost-effective and timely way possible.